Investors & Media

Investors & Media

Welcome to our investor page

Harnessing the immune system’s full potential to fight human disease.

Biopharmaceutical New Technologies is a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. We exploit a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Our broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bi-specific checkpoint immuno-modulators, targeted cancer antibodies and small molecules. Based on our deep expertise in mRNA vaccine development and in-house manufacturing capabilities, we and our collaborators are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside a diverse oncology pipeline. BioNTech has established a broad set of relationships with multiple global pharmaceutical collaborators, including Genmab, Sanofi, Bayer Animal Health, Genentech, a member of the Roche Group, Regeneron, Genevant, Fosun Pharma, and Pfizer.


Press Releases

4 August 2021

BioNTech Completes Acquisition of Kite’s Neoantigen TCR Cell Therapy R&D Pl..

2 August 2021

BioNTech to Report Second Quarter Financial Results and Operational Update on A..

26 July 2021

BioNTech Provides Update on Plans to Develop Sustainable Solutions to Address I..

Press releases (more)

Upcoming Events

August 9, 2021 at 8:00 AM EDT

Second Quarter 2021 Earnings Call

August 12, 2021

Canaccord Genuity Growth Conference

September 13 - September 15, 2021

H.C. Wainwright Annual Global Investment Conference

Upcoming events (more)

Stock Quote

Aug 5, 2021 /

Data Provided by Refinitiv. Minimum 15 minutes delayed.